Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020396 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 579
- Enrollment target
NCT01020396: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01020396 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 579 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020396, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 579 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical equivalence in the treatment of bacterial vaginosis.
Interventions
- DRUG Metronidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2002-01 |
| Est. Completion | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01020396
The ClinicalTrials.gov registry entry for NCT01020396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metronidazole is the first listed.
NCT01020396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01020396 about?
NCT01020396 is a clinical study titled "Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis". The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical equivalence in the treatme...
What is the current status of trial NCT01020396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 579 participants. The study started on 2002-01. Estimated completion is 2003-03.
What interventions are being tested in trial NCT01020396?
The interventions under investigation include: Metronidazole (DRUG).
Who is sponsoring clinical trial NCT01020396?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.